Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
ADBE Adobe Inc
GBTC Grayscale Bitcoin Trust (BTC)
GPN Global Payments Inc
BAC Bank of America Corp
BSRR Sierra Bancorp
MSI Motorola Solutions Inc
ESI Element Solutions Inc
INVZW Innoviz Technologies Equity Warrant Exp 05 April 2026 *W EXP 04/05/2026
BEN Franklin Resources Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Price
Delayed
$4.28
Day's Change
-0.175 (-3.93%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.44
Day's Low
4.21
Volume
(Light)

Today's volume of 286,948 shares is on pace to be much lighter than RLMD's 10-day average volume of 713,075 shares.

286,948
Latest Earnings Beat Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 10, 2022
-$1.31Q3 Consensus
of 7 analysts
-$1.45Difference from
consensus
9.66%
Q4 Earnings
will announce
(Unconfirmed) March 21, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

RLMD's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.